BAL- dimercaprol injection
Akorn, Inc.

---------

BAL in Oil Ampules
DIMERCAPROL INJECTION, USP

BAL (2,3-dimercaptop-1-propanol) 10%, Benzyl Benzoate 20%, in Peanut Oil

C₃H₈OS₂   Molecular Weight 124.22
CH₂CHCH₂OH
\  /SH  SH

Rx only

DESCRIPTION
Dimercaprol Injection USP is a colorless or almost colorless liquid chelating agent having a disagreeable, mercaptan-like odor. Each 1 mL sterile BAL in Oil (Dimercaprol Injection USP) contains: 100 mg Dimercaprol in 200 mg Benzyl Benzoate and 700 mg Peanut Oil.

CLINICAL PHARMACOLOGY
The sulfhydryl groups of dimercaprol form complexes with certain heavy metals thus preventing or reversing the metallic binding of sulfhydryl-containing enzymes. The complex is excreted. The sustained presence of dimercaprol promotes continued excretion of the metallic poisons - arsenic, gold and mercury. It is also used in combination with Edetate Calcium Disodium Injection USP to promote the excretion of lead.

INDICATIONS
BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP.

Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning.

Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys.

CONTRAINDICATIONS
BAL in Oil (Dimercaprol Injection USP) is contraindicated in most instances of hepatic insufficiency with the exception of postarsenical jaundice. The drug should be discontinued or used only with extreme caution if acute renal insufficiency develops during therapy.

WARNINGS
There may be local pain at the site of the injection. A reaction apparently peculiar to children is fever
which may persist during therapy. It occurs in approximately 30% of children. A transient reduction of the percentage of polymorphonuclear leukocytes may also be observed.

PRECAUTIONS
Because the dimercaprol-metal complex breaks down easily in an acid medium, production of an alkaline urine affords protection to the kidney during therapy. Medicinal iron should not be administered to patients under therapy with BAL in Oil (Dimercaprol Injection USP).

BAL in Oil Ampules is formulated with peanut oil. Peanut oil may cause allergic reactions in some individuals. Physicians should use caution in prescribing BAL in Oil Ampules for peanut-sensitive patients. Medication and equipment necessary to treat allergic reactions should be available if the product is administered to peanut-allergic patients.

Pregnancy Category C
Animal reproduction studies have not been conducted with BAL in Oil. It is also not known whether BAL in Oil can cause fetal harm when administered to a pregnant woman, or can affect reproduction capacity. BAL in Oil should be given to a pregnant woman only if clearly needed.

It is not known whether this drug is excreted in human milk. However, because many drugs are excreted in human milk, caution should be exercised when BAL in Oil is administered to a nursing woman.

ADVERSE REACTIONS
One of the most consistent responses to Dimercaprol Injection USP is a rise in blood pressure accompanied by tachycardia. This rise is roughly proportional to the dose administered. Doses larger than those recommended may cause other transitory signs and symptoms in approximate order of frequency as follows: (1) nausea and, in some instance, vomiting; (2) headache; (3) a burning sensation in the lips, mouth and throat; (4) a feeling of constriction, even pain, in the throat, chest, or hands; (5) conjunctivitis, lacrimation, blepharal spasm, rhinorrhea, and salivation; (6) tingling of the hands; (7) a burning sensation in the penis; (8) sweating of the forehead, hands and other areas; (9) abdominal pain; and (10) occasional appearance of painful sterile abscesses. Many of the above symptoms are accompanied by a feeling of anxiety, weakness, and unrest and often are relieved by administration of antihistamine.

DRUG ABUSE AND DEPENDENCE
Dimercaprol Injection USP is not a controlled substance listed in any other Drug Enforcement Administration schedules. Its use is not known to lead to dependence or abuse.

OVERDOSE
Dosage exceeding 5 mg/kg will usually be followed by vomiting, convulsions and stupor, beginning within 30 minutes and subsiding within 6 hours following injection.


DOSAGE AND ADMINISTRATION
By deep intramuscular injection only. For mild arsenic or gold poisoning, 2.5 mg/kg of body weight four times daily for two days, two times on the third day, and once daily thereafter for ten days; for severe arsenic or gold poisoning, 3 mg/kg every four hours for two-days, four times on the third day, then twice daily thereafter for ten days. For mercury poisoning, 5 mg/kg initially, followed by 2.5 mg/kg one or two times daily for ten days. For acute lead encephalopathy, 4 mg/kg body weight is given alone
in the first dose and thereafter at four-hour intervals in combination with Edetate Calcium Disodium Injection USP administered at a separate site. For less severe poisoning the dose can be reduced to 3 mg/kg after the first dose. Treatment is maintained for two to seven days depending on clinical response. Successful treatment depends on beginning injections at the earliest possible moment and on the use of adequate amounts at frequent intervals. Other supportive measures should always be used in conjunction with BAL in Oil (Dimercaprol Injection USP) therapy.

BAL in Oil should be inspected visually for particulate matter and discoloration prior to administration.

**HOW SUPPLIED**

3 mL (100 mg/mL) ampules, box of 10 (NDC 17478-526-03).

**STORAGE:** Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

**ANIMAL TOXICOLOGY**

The intramuscular LD$_{50}$ in rats is approximately 105 mg/kg; intraperitoneally 140 mg/kg. The intraperitoneal LD$_{80}$ in mice is approximately 125 mg/kg.

*JR. PHARM. EXPER. THER., 87, Supplement Aug. 1946.*

Akorn

Manufactured by: Akorn, Inc.

Lake Forest, IL 60045

BL00N Rev. 06/16

Principal Display Panel Text for Container Label:

NDC 17478-526-03
BAL in Oil
DIMERCAPROL INJECTION, USP
100 mg/mL
For IM Use Only
Rx only 3 mL Ampule
Principal Display Panel Text for Carton Label:
NDC 17478-526-03
BAL in Oil
DIMERCAPROL INJECTION, USP
100 mg/mL
For Intramuscular Injection Only
10 Ampules (3 mL each)
Rx only Akorn Logo
BAL in Oil
DIMERCAPROL INJECTION, USP
100 mg/mL
For Intramuscular Injection Only

For Intramuscular Injection only. Direction for use enclosed.
Each mL of sterile solution contains:
100 mg Dimercaprol USP in 200 mg
Benzyl Benzoate and 700 mg peanut oil.
Storage: Store at 20° to 25°C (68° to 77°F)
[see USP Controlled Room Temperature].

Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:17478-526-03</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>INTRAMUSCULAR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimercaprol</td>
<td>Dimercaprol</td>
<td>100 mg in 1 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzyl Benzoate</td>
<td>200 mg in 1 mL</td>
</tr>
<tr>
<td>Peanut Oil</td>
<td>700 mg in 1 mL</td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:17478-526-03</td>
<td>10 in 1 CARTON</td>
<td>05/01/2012</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3 mL in 1 AMPULE; Type 0: Not a Combination Product</td>
<td>05/01/2012</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA005939</td>
<td>05/01/2012</td>
<td></td>
</tr>
</tbody>
</table>

### Labeler

Labeler - Akorn, Inc. (062649876)

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akorn, Inc.</td>
<td>063434679</td>
<td>PACK(17478-526), LABEL(17478-526)</td>
<td></td>
</tr>
</tbody>
</table>

### Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akorn, Inc.</td>
<td>155135783</td>
<td>MANUFACTURE(17478-526), ANALYSIS(17478-526), STERILIZE(17478-526)</td>
<td></td>
</tr>
</tbody>
</table>

Revised: 11/2017